Prognostic Value of Estrogen and Progesterone Receptor Expression in Low Proliferative Human Epidermal Growth Factor Receptor 2- Negative Breast Cancer
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: Approximately two-thirds of breast cancer are estrogen-dependent cancers, which express estrogen receptor (ER)/progesterone receptor (PR). We investigated the prognostic value of ER/PR expression in human epidermal growth factor receptor 2 (HER2)-negative and low proliferative (Ki-67 ≤20%) breast cancer. Methods: A retrospective review was performed of 252 breast cancer data records, identified as ER/PR-positive, low Ki-67 proliferation index (≤20%) and HER2-negative. The data were divided into two subgroups: a strong luminal subgroup and a weak luminal subgroup, according to hormonal receptor expression status. Outcome measures included age at diagnosis, tumor size, tumor-node-metastasis (TNM) stage, ER, PR, Bcl-2, recurrent or metastatic characteristics, disease-free survival and overall survival, of each subgroup. Results: There were no statistical differences in TNM stage or tumor numbers between the two subgroups. The strong luminal subgroup was associated with a higher Bcl-2 expression (p<0.001). The weak luminal subgroup was associated with more frequent neural invasion (p=0.051) and lung (p=0.031), liver (p=0.031) and brain (p=0.033) metastases, than the strong luminal subgroup. Disease-free survival was significantly longer in the strong luminal subgroup than weak luminal subgroup (p=0.015). Overall survival was also significantly improved in the strong luminal subgroup relative to the weak luminal subgroup (p=0.014). Conclusion: The weak luminal subgroup showed worse prognosis than the strong luminal subgroup, among ER/PR-positive HER2-negative low proliferative breast cancer patients. Weak ER or PR expression, can be considered a poor prognostic factor in ER/PR-positive HER2-negative low proliferative breast cancer.
Abstract
Purpose: Approximately two-thirds of breast cancer are estrogen-dependent cancers, which express estrogen receptor (ER)/progesterone receptor (PR). We investigated the prognostic value of ER/PR expression in human epidermal growth factor receptor 2 (HER2)-negative and low proliferative (Ki-67 ≤20%) breast cancer. Methods: A retrospective review was performed of 252 breast cancer data records, identified as ER/PR-positive, low Ki-67 proliferation index (≤20%) and HER2-negative. The data were divided into two subgroups: a strong luminal subgroup and a weak luminal subgroup, according to hormonal receptor expression status. Outcome measures included age at diagnosis, tumor size, tumor-node-metastasis (TNM) stage, ER, PR, Bcl-2, recurrent or metastatic characteristics, disease-free survival and overall survival, of each subgroup. Results: There were no statistical differences in TNM stage or tumor numbers between the two subgroups. The strong luminal subgroup was associated with a higher Bcl-2 expression (p<0.001). The weak luminal subgroup was associated with more frequent neural invasion (p=0.051) and lung (p=0.031), liver (p=0.031) and brain (p=0.033) metastases, than the strong luminal subgroup. Disease-free survival was significantly longer in the strong luminal subgroup than weak luminal subgroup (p=0.015). Overall survival was also significantly improved in the strong luminal subgroup relative to the weak luminal subgroup (p=0.014). Conclusion: The weak luminal subgroup showed worse prognosis than the strong luminal subgroup, among ER/PR-positive HER2-negative low proliferative breast cancer patients. Weak ER or PR expression, can be considered a poor prognostic factor in ER/PR-positive HER2-negative low proliferative breast cancer.
참고문헌 (23)
- Fisher B, "A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors", N Engl J Med, 320, pp.479~484 (1989)
- Fisher B, "Systemic therapy in node-negative patients: updated findings from NSABP clinical trials. National Surgical Adjuvant Breast and Bowel Project", J Natl Cancer Inst Monogr, (11), pp.105~116 (1992)
- Baum M, "Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial", Lancet, 359, pp.2131~2139 (2002)
- Cuzick J, "Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial", Lancet Oncol, 11, pp.1135~1141 (2010)
- Musgrove EA, "Biological determinants of endocrine resistance in breast cancer", Nat Rev Cancer, 9, pp.631~643 (2009)
- Lauring J, "Evolving role of the estrogen receptor as a predictive biomarker: ESR1 mutational status and endocrine resistance in breast cancer", J Clin Oncol, 34, pp.2950~2952 (2016)
- Zhang M, "Analysis of factors affecting endocrine therapy resistance in breast cancer", Oncol Lett, 11, pp.379~384 (2016)
- Park C, "Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer", World J Surg Oncol, 14, pp.244~ (2016)
- Han-Sung Kim, "Analysis of the Potent Prognostic Factors in Luminal-Type Breast Cancer", Journal of Breast Cancer, 15(4), pp.401~406 (2012), 한국유방암학회[DOI]
- Allred DC, "Prognostic and predictive factors in breast cancer by immunohistochemical analysis", Mod Pathol, 11, pp.155~168 (1998)
- Phillips T, "Development of standard estrogen and progesterone receptor immunohistochemical assays for selection of patients for antihormonal therapy", Appl Immunohistochem Mol Morphol, 15, pp.325~331 (2007)
- Bustreo S, "Optimal Ki67 cut-off for luminal breast cancer prognostic evaluation: a large case series study with a long-term follow-up", Breast Cancer Res Treat, 157, pp.363~371 (2016)
- 박경미, "Silver-Enhanced In Situ Hybridization as an Alternative to Fluorescence In Situ Hybridization for Assaying HER2 Amplification in Clinical Breast Cancer", Journal of Breast Cancer, 14(4), pp.276~282 (2011), 한국유방암학회
- Fisher B, "Cancer of the breast: size of neoplasm and prognosis", Cancer, 24, pp.1071~1080 (1969)
- Braunstein LZ, "Molecular phenotype, multigene assays, and the locoregional management of breast cancer", Semin Radiat Oncol, 26, pp.9~16 (2016)
- Honma N, "Ki-67 evaluation at the hottest spot predicts clinical outcome of patients with hormone receptor-positive", HER2-negative breast cancer treated with adjuvant tamoxifen monotherapy, 2015, pp.22, 71~78
- Ellis MJ, "Neoadjuvant comparisons of aromatase inhibitors and tamoxifen: pretreatment determinants of response and on-treatment effect", J Steroid Biochem Mol Biol, 86, pp.301~307 (2003)
- Callagy GM, "Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer", BMC Cancer, 8, pp.153~ (2008)
- Dawson SJ, "BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received", Br J Cancer, 103, pp.668~675 (2010)
- Inwald EC, "Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry", Breast Cancer Res Treat, 139, pp.539~552 (2013)
- Balduzzi A, "Survival outcomes in breast cancer patients with low estrogen", progesterone receptor expression, 2014, pp.14, 258~264
- Early Breast Cancer Trialists’ Collaborative Group, "Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials", Lancet, 378, pp.771~784 (2011)
- Ono M, "Prognostic significance of progesterone receptor expression in estrogen-receptor positive, HER2-negative, node-negative invasive breast cancer with a low Ki-67 labeling index", Clin Breast Cancer, 17, pp.41~47 (2017)